Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug initiatives to improve cognitive function.

Stephen R Marder1

  • 1Semel Institute of Neuroscience and Human Behavior at UCLA and the Mental Illness Research, Education, and Clinical Center (MIRECC), West Los Angeles VA Healthcare Center, Los Angeles, CA 90073, USA. marder@ucla.edu

The Journal of Clinical Psychiatry
|September 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a Pluralistic Model for the Schizophrenia Spectrum-Dopamine and Beyond.

JAMA psychiatry·2026
Same author

A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction.

Schizophrenia bulletin open·2026
Same author

A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms.

Schizophrenia bulletin open·2026
Same author

Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia.

Schizophrenia research·2026
Same author

Finding a Medication for Negative Symptoms in Schizophrenia: Why So Many Failures?

The American journal of psychiatry·2026
Same author

Rethinking Antipsychotic Comparisons: The Role of Prior Exposure and Tolerability.

The American journal of psychiatry·2026

New research initiatives aim to improve treatments for schizophrenia, focusing on cognitive function and social competence. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) program seeks to develop novel therapies beyond symptom management.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Medication development for schizophrenia has lagged since the 1950s.
  • Current antipsychotics manage positive symptoms but often fail to improve cognitive and functional outcomes.
  • There is a critical need for treatments addressing cognitive impairment and social deficits in schizophrenia.

Purpose of the Study:

  • To establish research priorities for developing new treatments for schizophrenia.
  • To foster collaboration between academia, government, and industry to advance schizophrenia therapeutics.
  • To identify and validate targets for novel medications aimed at improving cognition and function.

Main Methods:

  • Convened experts from diverse sectors to discuss treatment development strategies.

Related Experiment Videos

  • Focused on improving cognitive abilities and social competence as key treatment targets.
  • Initiated efforts in adjunct medication research, regulatory pathways, outcome measurement, and symptom classification.

    • Main Results:

    • Achieved consensus on critical areas for schizophrenia treatment research.
    • Developed a framework for assessing cognitive and functional outcomes in clinical trials.
    • Identified promising targets for the development of new schizophrenia medications.

    Conclusions:

    • The MATRICS program has revitalized research into schizophrenia treatments.
    • A multi-faceted approach is necessary to address cognitive and functional deficits.
    • Future research should prioritize the development of therapies that enhance social and vocational outcomes.